Precision medicine promises to tailor health care to the individual. But what happens when entire communities are left out of ...

Return on Assets (ROA): Ionis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...